Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Iulia Voica

Allergy & Immunology Topeka, KS Medical Doctor

NPI 1386649143 CMS profile 153053

1123 Sw Gage Blvd, Topeka, KS 66604

Open in the dashboard

General payments

$3,226

174 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Iulia Voica of Topeka, KS is reported in the CMS Open Payments database as having received $3,226 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $137 6
2022 General $866 44
2021 General $716 43
2020 General $452 27
2019 General $1,055 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Iulia Voica
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Iulia Voica were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Iulia Voica Allergy & Immunology median Middle half National median
2019 $1,055 $594 $163–$1,512 $163
2020 $452 $426 $106–$1,233 $114
2021 $716 $638 $157–$1,708 $132
2022 $866 $790 $205–$1,961 $149
2023 $137 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $769 36 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $376 16 payments
  3. Allergan Inc. $301 10 payments
  4. Regeneron Healthcare Solutions, Inc. $218 13 payments
  5. GlaxoSmithKline, LLC. $215 14 payments
  6. OptiNose US, Inc. $211 12 payments
  7. Novartis Pharmaceuticals Corporation $191 13 payments
  8. CSL Behring $157 7 payments
  9. Shire North American Group Inc $144 12 payments
  10. Amgen Inc. $117 8 payments
  11. Other $525 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,226 174 payments
Products named General payments · program years 2019–2023
  1. TAKHZYRO $376 22 payments
  2. FASENRA Respiratory $350 16 payments
  3. FASENRA Respiratory $243 10 payments
  4. BOTOX COSMETIC $240 7 payments
  5. XOLAIR $230 16 payments
  6. DUPIXENT Inflammation And Immunology $218 13 payments
  7. Xhance $211 12 payments
  8. Hizentra $157 7 payments
  9. DUPIXENT Immunology $142 10 payments
  10. CUVITRU $133 5 payments
  11. Other $1,063 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record